Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Antileishmanial Activity of Aloe Vera Leaf Exudates: In Vitro and in Vivo



Shamsi H1 ; Shaddel M1 ; Yakhchali M2 ; Akbarzadeh M3 ; Raoufi N4 ; Tavakoli P1 ; Dastgheib M5 ; Dastgheib M5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Parasitology and Mycology, Faculty of Medicine, AJA University of Medical Sciences, Tehran, Iran
  2. 2. Departments of Pathobiology, Faculty of Veterinary Medicine, Urmia University, Urmia, Iran
  3. 3. Cellular and Molecular Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  4. 4. Department of Biology, Faculty of Basic Sciences, Islamic Azad University, Lahijan Branch, Iran
  5. 5. Department of Pharmacology, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
  6. 6. Department of Dermatology, Razi Hospital, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Source: Iranian Journal of Dermatology Published:2019

Abstract

Background: According to the drug resistance and side effects of the standard treatments for leishmaniasis, achieving effective treatment with less side effects and more benefits is of paramount importance. The present study aimed to evaluate the effect of Aloe vera leaf exudate on Leishmania major under in vitro and in vivo models, in inbred BALB/c mice. Methods: Different concentrations of both Aloe vera leaf exudates (AVL) and the standard drug meglumine antimoniate (Glucantime®; Sanofi-Aventis, France) were prepared (9.375l, 18.75, 37.5, 75, 150, and 300 μg/ml) for in vitro model and then were applied to the fixed number of promastigotes. The promastigotes were counted after 24, 48, and 72 h. The viability of promastigotes was tested by MTT. A total of 20 mice with cutaneous leishmaniasis were divided into four groups for in vivo model, 1: positive group (treatment with Glucantime®), 2: negative group (without treatment), and 3 and 4: experimental groups (treatment with AVL1% and AVL4%, respectively). The size of the ulcers were recorded at the beginning of the experiment on a weekly basis for four weeks. Results: The results of in vitro model indicated that both AVL and Glucantime® reduced the number of promastigotes such that there was the lowest number of parasites in the concentration 300 μg/ml of AVL and Glucantime®; however, the difference between them was not statistically significant. In vivo model demonstrated that AVL4% and Glucantime® decreased significantly the size of ulcers more than negative (P=0.000) and AVL1% groups (P=0.000 and P=0.004, respectively). Conclusions: There was no significant difference between AVL4% and Glucantime® (P=0.634). Therefore, AVL could control the Leishmania major. © 2019, Iranian Society of Dermatology. All rights reserved.